NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2015 by Naestved Hospital
University of Southern Denmark
Region Zealand
Information provided by (Responsible Party):
Julie K. G. Stryhn, Naestved Hospital Identifier:
First received: January 22, 2014
Last updated: April 15, 2015
Last verified: April 2015

Previously, studies have shown that children of women with thyroid autoantibodies experience more birth complications and poorer health in their first days. Studies have also shown later signs of cognitive developmental challenges (risk of attention deficit/hyperactivity problems) among children of mothers with autoimmune thyroid disease. In Denmark there is no formalized screening or treatment of subclinical thyroid disease - with or without Thyroid Peroxidase Antibodies (TPO-antibodies) - among pregnant women.

The hypothesis of this study is that the offspring of women with subclinical thyroid disease have a mitochondria-dysfunction which leads to more complications during birth, poorer health and well-being in the early childhood. The investigators will test this by recruiting mothers by a blood sample in the third trimester of pregnancy, screen the cord blood at birth and later on test the children with Bayley test two times in the early childhood.

Subclinical Hypothyroidism
Autoimmune Thyroid Disease
Alteration of Mitochondrial Membrane

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease

Resource links provided by NLM:

Further study details as provided by Naestved Hospital:

Primary Outcome Measures:
  • Mitochondrial function [ Time Frame: Delivery ] [ Designated as safety issue: No ]
    Maternal and cord blood. Analyses will be run by flow cytometry

Secondary Outcome Measures:
  • Perinatal complications [ Time Frame: At birth ] [ Designated as safety issue: No ]
    Apgar score, cord pH, need of CPAP, resuscitation, low blood sugar, cramps, death

  • Well-being [ Time Frame: Age 0-15 months ] [ Designated as safety issue: No ]
    Admissions to the hospital due to icterus, difficulties eating, weight loss or metabolic disease will be used as measures of early childhood adverse effects

  • Weight and height [ Time Frame: Age 0-15 months ] [ Designated as safety issue: No ]
    Weight and height will be used as measures for well-being

  • Motor development [ Time Frame: Age 0-15 months ] [ Designated as safety issue: No ]
    By parental registration of motor development milestones and by Bayley test

  • Cognitive development [ Time Frame: Age 1 and 15 months ] [ Designated as safety issue: No ]
    By Bayley-test

  • Birth complications [ Time Frame: Birth ] [ Designated as safety issue: No ]
    Hemorrhage >500 ml, abruptio placentae, pre-eclampsia

Biospecimen Retention:   Samples With DNA
Blood samples from 120 mothers and - if possible - their children´s cords will be stored for 15 years for supplementary analyses

Estimated Enrollment: 120
Study Start Date: January 2014
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Autoimmune thyroid disease
60 pregnant women with subclinical hypothyroidism with or without TPO-antibodies, and their offspring.
Healthy controls
60 pregnant women without thyroid disease or any other metabolic disorders, and their offspring.

Detailed Description:
Prior to a planned caesarean section, maternal blood samples are drawn and at the caesarean, cord blood samples are drawn, when the cord is clamped and cut. Thyreotropin, free T3, free T4, anti-TPO and lipids are measured on maternal as well as cord samples. Flow cytometry is performed to measure mitochondrial function. At age 6 months and 15 months the child´s development is evaluated by the Bayley-III test.

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study population will be selected among pregnant women in region Zealand that will give birth by cesarean section

Inclusion Criteria:

  • Singleton pregnancy, clinically healthy

Exclusion Criteria:

  • Twin-pregnancy, metabolic disorder, medication or other diseases with a potential adverse impact on the pregnancy and fetus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02061111

Gynaecologic-Obstetrics Department Naestved Hospital Recruiting
Naestved, Denmark, 4700
Contact: Julie Stryhn, MD    +45 56514437   
Principal Investigator: Julie Stryhn, MD         
Sponsors and Collaborators
Naestved Hospital
University of Southern Denmark
Region Zealand
Principal Investigator: Julie Stryhn, MD Naestved Hospital
Study Chair: Jan Kvetny, Professor MD Naestved Hospital
  More Information

No publications provided

Responsible Party: Julie K. G. Stryhn, MD, Naestved Hospital Identifier: NCT02061111     History of Changes
Other Study ID Numbers: SJ-361
Study First Received: January 22, 2014
Last Updated: April 15, 2015
Health Authority: Denmark: Danish Dataprotection Agency
Denmark: The Regional Committee on Biomedical Research Ethics

Keywords provided by Naestved Hospital:
Mitochondria Function
Subclinical Thyroid Disease
Thyroid Disease In Pregnancy
Children´s Development

Additional relevant MeSH terms:
Hashimoto Disease
Thyroid Diseases
Endocrine System Diseases
Thyroiditis, Autoimmune processed this record on November 27, 2015